Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66

Rhea-AI Filing Summary

Fulcrum Therapeutics director Robert J. Gould received a stock option grant for 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036. It was granted as compensation, not through an open-market transaction.

According to the terms, all 32,000 shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual meeting of stockholders after that date, as long as Gould continues to serve the company. Following this grant, his reported option holdings from this filing total 32,000 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gould Robert J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 32,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 32,000 shares Exercise price: $3.66 per share Expiration date: June 29, 2036 +1 more

4 metrics

Option grant size 32,000 shares Stock Option (right to buy) granted June 30, 2026

Exercise price $3.66 per share Exercise price for 32,000 stock options

Expiration date June 29, 2036 Option term end date

Total options after grant 32,000 options Total derivative holdings reported following transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 3.6600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"is scheduled to vest with respect to all shares on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"immediately prior to the first annual meeting of stockholders occurring after the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:32 PM Accepted by SEC EDGAR 07/02/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gould Robert J

(Last) (First) (Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.66	06/30/2026		A		32,000		(1)	06/29/2036	Common Stock	32,000	$0.00	32,000	D

Explanation of Responses:

1. This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

	/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report for Robert J. Gould?

Fulcrum Therapeutics reported that director Robert J. Gould received a stock option grant for 32,000 shares. The options give him the right to buy common stock at a fixed exercise price as part of his compensation, rather than an open-market purchase.

What is the exercise price and size of Robert J. Gould’s new Fulcrum Therapeutics options?

Robert J. Gould was granted options covering 32,000 shares of Fulcrum Therapeutics common stock at an exercise price of $3.66 per share. This means he can purchase those shares at $3.66, regardless of future market price, once the options vest.

When do Robert J. Gould’s Fulcrum Therapeutics option grants vest?

All 32,000 option shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date. They may instead vest earlier, immediately before the first annual meeting of stockholders after the grant date, if he continues serving the company.

When do the newly granted Fulcrum Therapeutics options to Robert J. Gould expire?

The stock options granted to Robert J. Gould expire on June 29, 2036. After that expiration date, he can no longer use the options to purchase Fulcrum Therapeutics common stock at the $3.66 exercise price specified in the grant.

Is Robert J. Gould’s Fulcrum Therapeutics Form 4 transaction a market buy or sell?

The Form 4 reports a grant of stock options to Robert J. Gould, not a market trade. It reflects a compensation-related acquisition of derivative securities, rather than an open-market purchase or sale of Fulcrum Therapeutics common stock.